MG
STOK icon

Michael Gelband’s Stoke Therapeutics STOK Stock Holding History

Michael Gelband’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.24M Buy
+129,660
New +$4.16M 0.03% 552
2022
Q4 		– Sell
-15,702
Closed -$202K – 2108
2022
Q3 		$202K Buy
+15,702
New +$250K ﹤0.01% 1637
2021
Q1 		– Sell
-4,944
Closed -$306K – 2583
2020
Q4 		$306K Buy
+4,944
New +$227K ﹤0.01% 1532

Other funds holding STOK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Michael Gelband's STOK Position: Q2 2026 in Review

Michael Gelband opened a new position in Stoke Therapeutics (STOK) in Q2 2026: 129,660 shares worth $4.24M. The stake represents 0.03% of the portfolio and ranks #552 among its holdings. This is a return to the name: Michael Gelband previously reported a position in STOK as recently as Q3 2022.

Michael Gelband first reported a position in STOK in Q4 2020 and has held it in 3 quarters since. 196 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • Michael Gelband held 129,660 shares of Stoke Therapeutics worth $4.24M as of Q2 2026.
  • Stoke Therapeutics was a new Michael Gelband position in Q2 2026.
  • Stoke Therapeutics made up 0.03% of Michael Gelband's portfolio in Q2 2026, its #552 holding.
  • Michael Gelband first reported a position in Stoke Therapeutics in Q4 2020 and has held it in 3 quarters since.
  • 196 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.